Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Pacira Pharm Inc (PCRX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 1,531,610
  • Shares Outstanding, K 37,280
  • Annual Sales, $ 249,000 K
  • Annual Income, $ 1,860 K
  • 36-Month Beta 2.31
  • Price/Sales 5.61
  • Price/Book 7.13

Price Performance

See More
Period Period Low Period High Performance
30.65 +27.90%
on 12/28/16
41.75 -6.11%
on 01/09/17
+5.90 (+17.72%)
since 12/23/16
29.95 +30.88%
on 12/02/16
41.75 -6.11%
on 01/09/17
+5.60 (+16.67%)
since 10/21/16
29.95 +30.88%
on 12/02/16
68.32 -42.62%
on 01/25/16
-26.81 (-40.62%)
since 01/22/16

Most Recent Stories

More News
Research Reports Coverage on Healthcare Stocks -- Pacira Pharma, Supernus Pharma, Lipocine, and IntelliPharmaCeutics today takes a closer look at the current performances of Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), Lipocine Inc. (NASDAQ: LPCN), and IntelliPharmaCeutics...

True North Provides Corporate Update at J.P. Morgan Healthcare Conference

--Highlights Potential for TNT009 in Other Rare Diseases including non-Hematologic Indications

Pacira Pharmaceuticals, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the 35 Annual J.P. Morgan Healthcare...

Pacira Pharmaceuticals and GeneAlign Announce Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a joint endeavor with GeneAlign, a therapeutic management and solutions company working to revolutionize personalized medicine through a patient-specific...

American College of Surgeons Launches Education Program on Opioids and Surgery: Use, Abuse, and Alternatives

The American College of Surgeons (ACS) today announced a new multifaceted initiative to improve the knowledge and management of pain in surgical patients with a focus on opioid risk and non-opioid alternatives....

Research Reports Initiation on Healthcare Stocks -- Perrigo, Pacira Pharma, Supernus Pharma, and PerkinElmer

This morning, has lined up the following healthcare stocks for assessment following a positive Monday's session where gains were broad based as all nine sectors ended the session in green:...

Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL(R) in Total Knee Replacement Surgery

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today introduced a revolutionary new virtual reality simulation intended to provide clinicians with an immersive, hands-on training experience to reinforce the...

Pacira (PCRX) Misses Q3 Earnings Estimates, Beats on Sales

Pacira Pharmaceuticals, Inc. (PCRX) reported third-quarter 2016 earnings of 2 cents (including the impact of stock-based compensation).

Pacira Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results

-- Total Net Revenues Up 10% Year-Over-Year --

What Falling Estimates & Price Mean for Pacira Pharmaceuticals (PCRX)

Pacira Pharmaceuticals (PCRX) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Support & Resistance

2nd Resistance Point 41.20
1st Resistance Point 40.20
Last Price 39.20
1st Support Level 38.45
2nd Support Level 37.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.